title: Synthesis, characterization and anticancer activity of certain 3-{4-(5-mercapto-1,3,4-oxadiazole-2-yl)phenylimino}indolin-2-one derivatives.
abstract: A series of 5- or 7-substituted 3-{4-(5-mercapto-1,3,4-oxadiazol-2-yl)phenylimino}-indolin-2-one derivatives were synthesized by treating 5-(4-aminophenyl)-1,3,4-oxadiazole-2-thiol with different isatin derivatives. The newly synthesized compounds were characterized on the basis of spectral (FT-IR, (1)H NMR, MS) analyses. All the synthesized derivatives were screened for anticancer activity against HeLa cancer cell lines using MTT assay. All the synthetic compounds produced a dose dependant inhibition of growth of the cells. The IC50 values of all the synthetic test compounds were found between 10.64 and 33.62 μM. The potency (IC50 values) of anticancer activity of compounds VIb-d was comparable with that of known anticancer agent, Cisplatin. Among the synthesized 2-indolinones, compounds VIb-d with halogen atom (electron withdrawing groups) at C5 position showed the most potent activity. These results indicate that C5 substituted derivatives may be useful leads for anticancer drug development in the future.
authors: University College of Pharmaceutical Sciences, Kakatiya University, Warangal, Andhra Pradesh 506 009, India.
authors: Rajyalakshmi
authors: R
authors: Gudipati
authors: Rama Narsimha Reddy
authors: RN
authors: Anreddy
authors: Sarangapani
authors: S
authors: Manda
keywords: 1,3,4-Oxadiazole; Anticancer activity; Indole; Isatin; MTT; Schiff bases
references: Eur J Med Chem. 2005 Nov;40(11):1156-62
references: 15935518
references: Eur J Med Chem. 2003 Jun;38(6):633-43
references: 12832136
references: J Natl Cancer Inst. 1991 Jun 5;83(11):757-66
references: 2041050
references: Bioorg Med Chem. 2008 Feb 15;16(4):1822-31
references: 18248993
references: J Pharm Sci. 1994 Feb;83(2):246-8
references: 8169798
references: Bioorg Med Chem. 2005 Jun 1;13(11):3797-809
references: 15863006
references: Mutat Res. 2003 May 9;537(1):43-51
references: 12742506
references: Pharm Acta Helv. 1999 Dec;74(1):11-7
references: 10748620
references: Antiviral Res. 2006 Aug;71(1):24-30
references: 16621041
references: J Med Chem. 2001 Jun 7;44(12):2015-26
references: 11384246
references: Bioorg Med Chem. 2006 Feb 15;14(4):1236-46
references: 16242340
references: Bioorg Med Chem. 2007 Sep 1;15(17):5888-904
references: 17561405
references: Biochem Biophys Res Commun. 2000 Sep 16;276(1):379-84
references: 11006132
references: Acta Pharm. 2004 Mar;54(1):49-56
references: 15050044
references: Biol Pharm Bull. 2001 Oct;24(10):1149-52
references: 11642321
references: Anticancer Res. 2006 Sep-Oct;26(5A):3595-600
references: 17094488
references: Eur J Med Chem. 2008 Jan;43(1):1-7
references: 17499885
references: Farmaco. 1999 Sep 30;54(9):624-8
references: 10555264
references: Br J Cancer. 2003 Feb 10;88(3):470-7
references: 12569393
references: Eur J Med Chem. 2007 Jul;42(7):893-901
references: 17418454
references: J Med Chem. 1996 Jul 19;39(15):2907-14
references: 8709125
references: J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
references: 2359136